ZNF91

Summary

ZNF91 (zinc finger protein 91, HGNC:13166) is a protein-coding gene on chromosome 19p12, encoding Zinc finger protein 91 (Q05481). Transcription factor specifically required to repress SINE-VNTR-Alu (SVA) retrotransposons: recognizes and binds SVA sequences and represses their expression by recruiting a repressive complex containing TRIM28/KAP1.

The ZNF91 gene encodes a zinc finger protein of the KRAB (Kruppel-associated box) subfamily (Bellefroid et al., 1991, 1993 [PubMed 2023909] [PubMed 8467795]).

Source: NCBI Gene 7644 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 187 total
• Phenotypes (HPO): 4
• Transcription factor: yes — 52 downstream targets (CollecTRI)
• MANE Select transcript: NM_003430

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13166
Approved symbol	ZNF91
Name	zinc finger protein 91
Location	19p12
Locus type	gene with protein product
Status	Approved
Aliases	HPF7, HTF10
Ensembl gene	ENSG00000167232
Ensembl biotype	protein_coding
OMIM	603971
Entrez	7644

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 7 protein_coding_CDS_not_defined, 6 protein_coding, 1 retained_intron

ENST00000300619, ENST00000397082, ENST00000593292, ENST00000593341, ENST00000593645, ENST00000595533, ENST00000595893, ENST00000596528, ENST00000596989, ENST00000597458, ENST00000599281, ENST00000599743, ENST00000909304, ENST00000909305

RefSeq mRNA: 2 — MANE Select: NM_003430 NM_001300951, NM_003430

CCDS: CCDS42541, CCDS74322

Canonical transcript exons

ENST00000300619 — 4 exons

Exon	Start	End
ENSE00001415621	23357696	23362725
ENSE00002988952	23395325	23395471
ENSE00003588565	23374638	23374764
ENSE00003634793	23373742	23373837

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 98.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.4823 / max 660.2663, expressed in 1718 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
180272	21.4700	1718
180263	0.0123	3

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
type B pancreatic cell	CL:0000169	98.95	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.92	gold quality
lateral globus pallidus	UBERON:0002476	98.66	gold quality
heart right ventricle	UBERON:0002080	98.50	gold quality
postcentral gyrus	UBERON:0002581	98.36	gold quality
diaphragm	UBERON:0001103	98.31	gold quality
parietal lobe	UBERON:0001872	98.30	gold quality
pons	UBERON:0000988	98.22	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.15	gold quality
Brodmann (1909) area 46	UBERON:0006483	98.14	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.98	gold quality
jejunal mucosa	UBERON:0000399	97.76	gold quality
substantia nigra pars compacta	UBERON:0001965	97.70	gold quality
entorhinal cortex	UBERON:0002728	97.70	gold quality
colonic mucosa	UBERON:0000317	97.65	gold quality
biceps brachii	UBERON:0001507	97.55	gold quality
frontal pole	UBERON:0002795	97.54	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.46	gold quality
Brodmann (1909) area 10	UBERON:0013541	97.45	gold quality
gluteal muscle	UBERON:0002000	97.42	gold quality
jejunum	UBERON:0002115	97.41	gold quality
CA1 field of hippocampus	UBERON:0003881	97.37	gold quality
renal medulla	UBERON:0000362	97.30	gold quality
pigmented layer of retina	UBERON:0001782	97.30	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.26	gold quality
paraflocculus	UBERON:0005351	97.11	gold quality
vena cava	UBERON:0004087	97.10	gold quality
cerebellar vermis	UBERON:0004720	96.93	gold quality
superior surface of tongue	UBERON:0007371	96.83	gold quality
orbitofrontal cortex	UBERON:0004167	96.79	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7606	no	164.49
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

52 targets.

Target	Regulation
ADH1B
AFP
ALDOA
AP3B1
CALCA
CAMK2A
CAV1
CD34
CD74
CDH1
CDKN2B
DMPK
FCGR2B
FCGR3B	Repression
FGF18
GADD45A
GAL
GAST
GDNF
GFI1
GNAS
HLA-A
HLA-E
IFNB1
IGF2
IL2
IL3
IL4
INS
INSR

Upstream regulators (CollecTRI, top): ZNF143, ZNF331

miRNA regulators (miRDB)

81 targeting ZNF91, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-548A-3P	99.76	70.58	3524

Literature-anchored findings (GeneRIF, showing 1)

• Hypoxic exosomal HIF-1alpha-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. (PMID:34294845)

Cross-species orthologs

30 orthologs

Organism	Symbol	Gene ID
danio_rerio	znf646	ENSDARG00000061424
danio_rerio	si:dkey-154p10.3	ENSDARG00000068366
danio_rerio	si:dkey-89b17.4	ENSDARG00000075545
danio_rerio	zgc:66472	ENSDARG00000075916
danio_rerio	si:ch211-148l7.4	ENSDARG00000094469
danio_rerio	znf576.1	ENSDARG00000097819
drosophila_melanogaster	Sry-delta	FBGN0003512
drosophila_melanogaster	az2	FBGN0025185
drosophila_melanogaster	hang	FBGN0026575
drosophila_melanogaster	CG3032	FBGN0029928
drosophila_melanogaster	CG2129	FBGN0030008
drosophila_melanogaster	CG11695	FBGN0030316
drosophila_melanogaster	CG8944	FBGN0030680
drosophila_melanogaster	CG7101	FBGN0030963
drosophila_melanogaster	CG1602	FBGN0033186
drosophila_melanogaster	CG18011	FBGN0033491
drosophila_melanogaster	CG12942	FBGN0033569
drosophila_melanogaster	CG8089	FBGN0033993
drosophila_melanogaster	indra	FBGN0035213
drosophila_melanogaster	CG10654	FBGN0036294
drosophila_melanogaster	CG6791	FBGN0037918
drosophila_melanogaster	CG17803	FBGN0038547
drosophila_melanogaster	CG12219	FBGN0043796
drosophila_melanogaster	CG30020	FBGN0050020
drosophila_melanogaster	pzg	FBGN0259785
drosophila_melanogaster	mld	FBGN0263490
drosophila_melanogaster	zf30C	FBGN0270924
caenorhabditis_elegans	ztf-15	WBGENE00011066
caenorhabditis_elegans		WBGENE00013734
caenorhabditis_elegans		WBGENE00015649

Paralogs (36): ZNF302 (ENSG00000089335), ZNF184 (ENSG00000096654), CTCF (ENSG00000102974), ZNF574 (ENSG00000105732), ZBTB24 (ENSG00000112365), ZNF142 (ENSG00000115568), CTCFL (ENSG00000124092), ZNF473 (ENSG00000142528), ZNF827 (ENSG00000151612), ZNF689 (ENSG00000156853), ZNF208 (ENSG00000160321), ZNF526 (ENSG00000167625), ZNF764 (ENSG00000169951), ZNF747 (ENSG00000169955), ZNF282 (ENSG00000170265), ZNF160 (ENSG00000170949), ZNF497 (ENSG00000174586), ZBTB34 (ENSG00000177125), ZNF771 (ENSG00000179965), ZNF48 (ENSG00000180035), ZNF594 (ENSG00000180626), ZBTB37 (ENSG00000185278), ZFP92 (ENSG00000189420), ZNF107 (ENSG00000196247), ZNF729 (ENSG00000196350), ZNF569 (ENSG00000196437), ZNF420 (ENSG00000197050), ZNF785 (ENSG00000197162), ZNF665 (ENSG00000197497), ZNF181 (ENSG00000197841), ZNF347 (ENSG00000197937), ZNF84 (ENSG00000198040), ZBTB48 (ENSG00000204859), ZNF845 (ENSG00000213799), ZNF99 (ENSG00000213973), ZNF688 (ENSG00000229809)

Protein

Protein identifiers

Zinc finger protein 91 — Q05481 (reviewed: Q05481)

Alternative names: Zinc finger protein HPF7, Zinc finger protein HTF10

All UniProt accessions (3): Q05481, M0QX31, M0R186

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor specifically required to repress SINE-VNTR-Alu (SVA) retrotransposons: recognizes and binds SVA sequences and represses their expression by recruiting a repressive complex containing TRIM28/KAP1. May also bind the promoter of the FCGR2B gene, leading to repress its expression; however, additional evidence is required to confirm this result in vivo.

Subcellular location. Nucleus.

Miscellaneous. ZNF91 is only present in primates and emerged in the last common ancestor of humans and Old-World monkeys. It underwent structural changes between 8-12 Million years ago, probably to improve the protein’s ability to bind and repress SINE-VNTR-Alu (SVA) retrotransposons elements.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q05481-1	1	yes
Q05481-2	2

RefSeq proteins (2): NP_001287880, NP_003421* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (59 total): zinc finger region 36, sequence variant 10, sequence conflict 10, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q05481-F1	72.09	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 131 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, HSIAO_HOUSEKEEPING_GENES, HANN_RESISTANCE_TO_BCL2_INHIBITOR_UP, YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_DN, ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP, chr19p12, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, WEIGEL_OXIDATIVE_STRESS_RESPONSE, FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN, RIGGI_EWING_SARCOMA_PROGENITOR_UP, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), transposable element silencing (GO:0010526), negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (5): DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
negative regulation of gene expression	1
retrotransposition	1
regulation of transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
negative regulation of transcription by RNA polymerase II	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription repressor activity	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

584 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF91	ZNF106	Q9H2Y7	815
ZNF91	ZPR1	O75312	765
ZNF91	LGALS4	P56470	470
ZNF91	ZNF208	O43345	433
ZNF91	TRIM28	Q13263	400
ZNF91	ZBTB35	P52739	384
ZNF91	LPXN	O60711	383
ZNF91	ZNF142	P52746	363
ZNF91	LCP1	P13796	348
ZNF91	TACSTD2	P09758	347
ZNF91	CEACAM6	P40199	342
ZNF91	CXADR	P78310	336
ZNF91	CTSF	Q9UBX1	336
ZNF91	ZNF212	Q9UDV6	320
ZNF91	SETDB1	Q15047	300

IntAct

12 interactions, top by confidence:

A	B	Type	Score
TRIM44	ODAD3	psi-mi:“MI:0914”(association)	0.530
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ZNF91	CHMP5	psi-mi:“MI:0915”(physical association)	0.370
ECE1	ZNF91	psi-mi:“MI:0915”(physical association)	0.370
HTT	ZNF91	psi-mi:“MI:0915”(physical association)	0.370
PURG	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZKSCAN8	ZNF320	psi-mi:“MI:0914”(association)	0.350
ZNF91	NDEL1	psi-mi:“MI:0915”(physical association)	0.000
ZNF91		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (18): ZNF91 (Affinity Capture-MS), ZNF91 (Affinity Capture-MS), ZNF91 (Affinity Capture-RNA), ZNF91 (Proximity Label-MS), ZNF91 (Affinity Capture-MS), ZNF91 (Affinity Capture-MS), ZNF91 (Affinity Capture-MS), ZNF91 (Affinity Capture-MS), ZNF91 (Proximity Label-MS), ZNF91 (Affinity Capture-MS), ZNF91 (Affinity Capture-MS), ZNF91 (Affinity Capture-MS), PRDX1 (Cross-Linking-MS (XL-MS)), ZNF91 (Proximity Label-MS), ZNF91 (Affinity Capture-RNA)

ESM2 similar proteins: A2VDQ7, A6NK75, A6NN14, A6NNF4, A8MQ14, A8MTY0, A8MXY4, B7Z6K7, E9QAG8, O43345, O75290, O75373, O75437, P0CJ79, P10751, P17017, P17019, P17035, P17038, P18749, P35789, P51522, Q03923, Q03938, Q05481, Q14585, Q3SYV7, Q4V348, Q5R5U3, Q5R8X1, Q5R9F0, Q5SXM1, Q6P5C7, Q6ZN08, Q6ZN57, Q6ZR52, Q86V71, Q86XN6, Q8IYB9, Q8N7Q3

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
ZNF91	“down-regulates quantity by repression”	FCGR3B	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

187 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	171
Likely benign	11
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

795 predictions. Top by Δscore:

Variant	Effect	Δscore
19:23374632:CCTTA:C	donor_loss	1.0000
19:23374633:CTTA:C	donor_loss	1.0000
19:23374634:TTAC:T	donor_loss	1.0000
19:23374635:TA:T	donor_loss	1.0000
19:23374636:A:AC	donor_gain	1.0000
19:23374636:AC:A	donor_gain	1.0000
19:23374637:C:CC	donor_gain	1.0000
19:23374637:C:G	donor_loss	1.0000
19:23374637:CC:C	donor_gain	1.0000
19:23374760:AGTCC:A	acceptor_gain	1.0000
19:23374761:GTCC:G	acceptor_gain	1.0000
19:23374762:TCC:T	acceptor_gain	1.0000
19:23374763:CC:C	acceptor_gain	1.0000
19:23374763:CCC:C	acceptor_gain	1.0000
19:23374764:CC:C	acceptor_gain	1.0000
19:23374765:C:CC	acceptor_gain	1.0000
19:23374766:T:A	acceptor_loss	1.0000
19:23374636:ACC:A	donor_gain	0.9900
19:23374637:CCC:C	donor_gain	0.9900
19:23395359:G:C	donor_gain	0.9900
19:23373736:ACCT:A	donor_loss	0.9800
19:23373737:CCTA:C	donor_loss	0.9800
19:23373738:CTAC:C	donor_loss	0.9800
19:23373739:TACC:T	donor_loss	0.9800
19:23373740:ACC:A	donor_loss	0.9800
19:23373741:CCTGT:C	donor_loss	0.9800
19:23373835:TACCT:T	acceptor_loss	0.9800
19:23373836:ACCTG:A	acceptor_loss	0.9800
19:23373838:CT:C	acceptor_loss	0.9800
19:23373839:T:G	acceptor_loss	0.9800

AlphaMissense

7902 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:23360978:A:C	F667L	0.986
19:23360978:A:T	F667L	0.986
19:23360980:A:G	F667L	0.986
19:23359718:A:C	F1087L	0.985
19:23359718:A:T	F1087L	0.985
19:23359720:A:G	F1087L	0.985
19:23359802:A:C	F1059L	0.977
19:23359802:A:T	F1059L	0.977
19:23359804:A:G	F1059L	0.977
19:23359970:A:C	F1003L	0.977
19:23359970:A:T	F1003L	0.977
19:23359972:A:G	F1003L	0.977
19:23360138:A:C	F947L	0.977
19:23360138:A:T	F947L	0.977
19:23360140:A:G	F947L	0.977
19:23361062:A:C	F639L	0.977
19:23361062:A:T	F639L	0.977
19:23361064:A:G	F639L	0.977
19:23360558:A:C	F807L	0.976
19:23360558:A:T	F807L	0.976
19:23360560:A:G	F807L	0.976
19:23362070:A:C	F303L	0.976
19:23362070:A:T	F303L	0.976
19:23362072:A:G	F303L	0.976
19:23361902:A:C	F359L	0.975
19:23361902:A:T	F359L	0.975
19:23361904:A:G	F359L	0.975
19:23360642:A:C	F779L	0.974
19:23360642:A:T	F779L	0.974
19:23360644:A:G	F779L	0.974

dbSNP variants (sampled 300 via entrez): RS1000048132 (19:23324324 T>C), RS1000068217 (19:23362982 C>G,T), RS1000103304 (19:23337585 A>C), RS1000118544 (19:23341280 A>C,G), RS1000145293 (19:23304565 C>T), RS1000245730 (19:23363241 G>A), RS1000296827 (19:23351117 G>C), RS1000303794 (19:23356991 G>A), RS1000323704 (19:23331980 C>A,T), RS1000357636 (19:23354912 G>A,T), RS1000381065 (19:23342943 A>G), RS1000413884 (19:23350843 T>A), RS1000424242 (19:23348717 A>G), RS1000495720 (19:23368377 G>A,C), RS1000514582 (19:23358622 C>T)

Disease associations

OMIM: gene MIM:603971 | disease phenotypes: MIM:256300, MIM:116200

GenCC curated gene-disease

Mondo (5): microcephaly (MONDO:0001149), familial nephrotic syndrome (MONDO:0002350), cataract (MONDO:0005129), inherited retinal dystrophy (MONDO:0019118), microphthalmia (MONDO:0021129)

Orphanet (1): OBSOLETE: Inherited retinal disorder (Orphanet:71862)

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly
HP:0000518	Cataract
HP:0000556	Retinal dystrophy
HP:0000568	Microphthalmia

GWAS associations

0 associations (top):

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D002386	Cataract	C11.510.245
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D008850	Microphthalmos	C11.250.566; C16.131.384.666
D058499	Retinal Dystrophies	C11.768.585.658

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, increases expression	3
sodium arsenite	decreases expression, increases expression	2
Formaldehyde	decreases expression, increases expression	2
Hydrogen Peroxide	affects expression, decreases expression	2
Tetrachlorodibenzodioxin	affects expression, affects cotreatment, increases expression	2
urushiol	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation	1
mono-(2-ethylhexyl)phthalate	increases abundance, increases methylation	1
afimoxifene	increases expression	1
tibolone	decreases expression	1
4-hydroxy-2-nonenal	decreases expression	1
nickel sulfate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	decreases expression	1
tebuconazole	decreases expression	1
K 7174	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, increases expression	1
Resveratrol	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	increases abundance, decreases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Coal	decreases expression, increases abundance	1
Coumestrol	decreases expression	1
Diethylhexyl Phthalate	increases abundance, increases methylation	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Methyl Methanesulfonate	increases expression	1
Selenium	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TZ52	HAP1 ZNF91 (-) 1	Cancer cell line	Male
CVCL_TZ53	HAP1 ZNF91 (-) 2	Cancer cell line	Male
CVCL_TZ54	HAP1 ZNF91 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00273221	PHASE4	UNKNOWN	Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial
NCT00312299	PHASE4	COMPLETED	Posterior Capsule Opacification Study
NCT00345046	PHASE4	COMPLETED	A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00347243	PHASE4	COMPLETED	Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical Intraocular Lenses
NCT00347503	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00348244	PHASE4	COMPLETED	Ketorolac vs. Steroid in the Prevention of CME
NCT00348270	PHASE4	COMPLETED	Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses
NCT00348582	PHASE4	COMPLETED	Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
NCT00348621	PHASE4	COMPLETED	A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
NCT00349583	PHASE4	COMPLETED	Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation
NCT00355446	PHASE4	COMPLETED	Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.
NCT00386438	PHASE4	COMPLETED	Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification
NCT00392275	PHASE4	COMPLETED	Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs
NCT00428363	PHASE4	COMPLETED	Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification
NCT00449267	PHASE4	COMPLETED	Aurolab Hydrophobic Foldable Intraocular Lens Study
NCT00459303	PHASE4	COMPLETED	Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof
NCT00469690	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects
NCT00576485	PHASE4	COMPLETED	Spherical Aberration and Contrast Sensitivity in IOLs
NCT00612729	PHASE4	COMPLETED	Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.
NCT00612781	PHASE4	COMPLETED	Yellow Versus White Study
NCT00630019	PHASE4	COMPLETED	Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
NCT00673803	PHASE4	COMPLETED	Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification
NCT00684138	PHASE4	COMPLETED	ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
NCT00698724	PHASE4	COMPLETED	Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
NCT00710905	PHASE4	TERMINATED	Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3
NCT00710931	PHASE4	COMPLETED	Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1
NCT00711347	PHASE4	COMPLETED	Intraoperative Floppy Iris Syndrome
NCT00712244	PHASE4	COMPLETED	DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00719732	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3
NCT00721253	PHASE4	COMPLETED	Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA
NCT00731640	PHASE4	COMPLETED	Contralateral ReSTOR / Monofocal or Phakic Eye
NCT00732030	PHASE4	COMPLETED	Low Cylinder Toric
NCT00758199	PHASE4	COMPLETED	Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
NCT00760058	PHASE4	WITHDRAWN	Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL
NCT00760487	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens
NCT00761488	PHASE4	WITHDRAWN	Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric
NCT00763360	PHASE4	COMPLETED	To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
NCT00786370	PHASE4	COMPLETED	Dexmedetomidine vs. Propofol for Cataract Surgery
NCT00786565	PHASE4	COMPLETED	Clinical Evaluation of a New Aspheric Intraocular Lens.